Ana Mendoza

Ana Mendoza

Auto-generated profile, based on publicly available information

Ana Mendoza

Hematology Department Hospital Universitario La Paz Madrid Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2023 in British Journal of Haematology
Verified
Journal Article
Open access
AMAna Mendoza
Ana Mendoza
MRMaría Teresa Álvarez Román
María Teresa Álvarez Román
EMElena Monzón‐Manzano
Elena Monzón‐Manzano
PAPaula Acuña
Paula Acuña
EAElena G. Arias‐Salgado
Elena G. Arias‐Salgado
NBNora Butta
Nora Butta
Summary: Despite the efficacy of splenectomy for chronic immune thrombocytopenia (ITP), its considerable failure rate and its possible related complications prove the need for further research into potential predictors of response. The platelet sequestration site determined by 111In‐labelled autologous platelet scintigraphy has been proposed to predict splenectomy outcome, but without standardisation in clinical practice. Here, we conducted a single‐centre study by analysing a cohort of splenectomised patients with ITP in whom 111In‐scintigraphy was performed at La Paz University Hospital in Madrid to evaluate the predictive value of the platelet kinetic studies. We also studied other factors that could impact the splenectomy outcome, such as patient and platelet characteristics. A total of 51 patients were splenectomised, and 82.3% responded. The splenic sequestration pattern predicted a higher rate of complete response up to 12 months after splenectomy (p = 0.005), with 90% sensitivity and 77% specificity. Neither age, comorbidities, therapy lines nor previous response to them showed any association with response. Results from the platelet characteristics analysis revealed a significant loss of sialic acid in platelets from the non‐responding patients compared with those who maintained a response (p = 0.0017). Our findings highlight the value of splenic sequestration as an independent predictor of splenectomy response.

Verified
Journal Article
Open access
PDF file
JBJose Manuel Martin de Bustamante
Jose Manuel Martin de Bustamante
AMAna Mendoza
Ana Mendoza
SLSamuel López-Muñoz
Samuel López-Muñoz
EFEugenia Garcia Fernandez
Eugenia Garcia Fernandez
PGPilar Gómez-Prieto
Pilar Gómez-Prieto
VJVictor Jimenez-Yuste
Victor Jimenez-Yuste
Recently, there have been reports of what could be a new lymphoproliferative entity: breast implant-associated Epstein–Barr virus positive (EBV+) diffuse large B-cell lymphoma (EBV+ BIA-DLBCL). The new World Health Organization classification has categorized it as fibrin-associated large B-cell lymphomas (FA-LBCLs); therefore, it could be referred to as breast implant-associated fibrin-associated large B-cell lymphomas (BIA-FA-LBCLs). Although the association between breast implants and lymphomas has been known since the mid-1990s, it has been almost exclusively breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Here, we describe the first case of BIA-FA-LBCL at our center, with a literature review of the clinical features, diagnosis and treatment approach of this lymphoma. We also explore the differential diagnosis of BIA-FA-LBCL, highlighting the diagnostic challenges and the reasons that have led these lymphomas to being labeled as a new face of FA-LBCL.

30 May 2025 in Haemophilia
Verified
Journal Article
Open access
AMAna Mendoza
Ana Mendoza
IRIsabel Rivas
Isabel Rivas
OHOlga Benítez Hidalgo
Olga Benítez Hidalgo
ACAna Rosa Cid
Ana Rosa Cid
MOMartin Olivieri
Martin Olivieri
MRMaría Teresa Álvarez Román
María Teresa Álvarez Román
Introduction: Patients with severe haemophilia A (HA) with no family history of haemophilia will be diagnosed upon their first bleeding event. Methods: Herein, we studied the effects of lack of family history in HA and the subsequent delay of diagnosis on bleeding pattern and early treatment, as well as on the risk of inhibitor development. For this purpose, data on 1237 severe HA patients with known family history (“positive” or “negative”), born between 2000 and 2022, were collected in 29 participating centres. Results: At diagnosis, 45.9% (554/1208) of patients had a positive family history of HA and 54.1% (654/1208) had a negative family history. A positive family history significantly shortened the time to diagnosis (8 months) and the treatment initiation (2 months). Prophylaxis was more frequently the first treatment in those with a positive family history compared to the negative family history group (21% vs. 13%). Bleeding was the main reason for first exposure day (ED) in both groups, but less frequently in the family history group than in those without a family history (67% vs. 80%). Positive family history was associated with fewer peak treatments at first five EDs (12% vs. 16%). In non‐inhibitor patients, bleeding occurred earlier in those with positive family history (9.2 months vs. 10.6 months). The inhibitor incidence was similar in both groups (33% vs. 30%), and a positive family history was associated with earlier inhibitor development (13 months vs. 15 months). Conclusion: The majority of patients presented without a family history of HA which led to a delayed diagnosis and treatment initiation.

26 May 2026 in Blood Reviews
Verified
Journal Article
Open access
IHIgnacio Hernández-Abad
Ignacio Hernández-Abad
RARaquel Ancos-Pintado
Raquel Ancos-Pintado
AMAna Mendoza
Ana Mendoza
ÁBÁlvaro Basterra-García
Álvaro Basterra-García
RGRoberto García-Vicente
Roberto García-Vicente
MLMaría J. Ledesma-Carbayo
María J. Ledesma-Carbayo
Artificial intelligence (AI) is transforming morphological assessment in hematologic malignancies by enabling automated cell classification, detection of disease-specific features, and prediction of genetic alterations from blood and bone marrow smear images. Deep learning models have achieved expert-level performance in identifying malignant patterns, uncovering morphologic-molecular associations, and providing patient-level diagnoses through multiple instance learning approaches. This review summarizes recent advances in AI-driven morphological analysis across myeloid and lymphoid neoplasms, emphasizing their impact on diagnosis and disease classification. We further examine emerging evidence linking image-derived features, such as nuclear texture, cytoplasmic granularity, and spatial cell organization, to molecular and prognostic variables. In addition, we discuss enabling technologies, including virtual staining and interpretability methods, that support clinical integration. Finally, we address key challenges, including data heterogeneity, the need for prospective validation, and interdisciplinary collaboration. AI-powered, explainable morphological analysis has the potential to advance precision hematology and personalized patient management.

6 November 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
AMAna Mendoza
Ana Mendoza
MCMaría Gema Crespo
María Gema Crespo
MMMarta Morado
Marta Morado